LUC00112I2 - - Google Patents
Download PDFInfo
- Publication number
- LUC00112I2 LUC00112I2 LU00112C LUC00112C LUC00112I2 LU C00112 I2 LUC00112 I2 LU C00112I2 LU 00112 C LU00112 C LU 00112C LU C00112 C LUC00112 C LU C00112C LU C00112 I2 LUC00112 I2 LU C00112I2
- Authority
- LU
- Luxembourg
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35332310P | 2010-06-10 | 2010-06-10 | |
| PCT/US2011/039381 WO2011156324A1 (fr) | 2010-06-10 | 2011-06-07 | Anticorps anti-cgrp |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LUC00112I1 LUC00112I1 (fr) | 2019-04-10 |
| LUC00112I2 true LUC00112I2 (fr) | 2019-12-27 |
Family
ID=45096388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU00112C LUC00112I2 (fr) | 2010-06-10 | 2019-04-09 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9073991B2 (fr) |
| EP (2) | EP2579894B1 (fr) |
| JP (2) | JP6021806B2 (fr) |
| KR (1) | KR101489566B1 (fr) |
| CN (2) | CN102946905B (fr) |
| AR (1) | AR081434A1 (fr) |
| AU (1) | AU2011265050B2 (fr) |
| BR (1) | BR112012031501B1 (fr) |
| CA (1) | CA2802102C (fr) |
| CY (2) | CY1119789T1 (fr) |
| DK (1) | DK2579894T3 (fr) |
| EA (1) | EA022931B1 (fr) |
| ES (2) | ES2656000T3 (fr) |
| HK (1) | HK1203211A1 (fr) |
| HR (1) | HRP20171992T1 (fr) |
| HU (2) | HUE038135T2 (fr) |
| IL (2) | IL222885B (fr) |
| JO (1) | JO3330B1 (fr) |
| LT (2) | LT2579894T (fr) |
| LU (1) | LUC00112I2 (fr) |
| ME (1) | ME02862B (fr) |
| MX (2) | MX363209B (fr) |
| NL (1) | NL300979I2 (fr) |
| NO (2) | NO2579894T3 (fr) |
| NZ (1) | NZ603607A (fr) |
| PL (1) | PL2579894T3 (fr) |
| PT (1) | PT2579894T (fr) |
| RS (1) | RS56638B1 (fr) |
| SG (1) | SG185648A1 (fr) |
| SI (1) | SI2579894T1 (fr) |
| TW (1) | TWI423818B (fr) |
| UA (1) | UA109658C2 (fr) |
| WO (1) | WO2011156324A1 (fr) |
| ZA (1) | ZA201208996B (fr) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101309704B (zh) | 2005-11-14 | 2012-10-10 | 礼纳特神经系统科学公司 | 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 |
| CA2716424C (fr) | 2008-03-04 | 2015-04-28 | Pfizer Limited | Procedes de traitement d'une douleur chronique |
| AU2010288194B2 (en) | 2009-08-28 | 2013-08-29 | Teva Pharmaceuticals International Gmbh | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
| AR081434A1 (es) * | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
| DK2709663T3 (da) | 2011-05-20 | 2019-05-20 | Alderbio Holdings Llc | Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere |
| AU2012258976B8 (en) | 2011-05-20 | 2017-07-20 | H. Lundbeck A/S | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| HUE055505T2 (hu) | 2011-05-20 | 2021-11-29 | H Lundbeck As | Anti-CGRP készítmények és alkalmazásuk |
| PL2888283T3 (pl) | 2012-08-24 | 2019-03-29 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| US9896502B2 (en) * | 2014-03-21 | 2018-02-20 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| SG11201703238TA (en) | 2014-10-24 | 2017-05-30 | Merck Sharp & Dohme | Co-agonists of the glucagon and glp-1 receptors |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
| AR104847A1 (es) | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| JP6592600B2 (ja) * | 2015-10-30 | 2019-10-16 | イーライ リリー アンド カンパニー | 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用 |
| CN105483091A (zh) * | 2015-12-29 | 2016-04-13 | 天津三箭生物技术股份有限公司 | 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| WO2017132062A1 (fr) * | 2016-01-28 | 2017-08-03 | Eli Lilly And Company | Anticorps anti-cgrp et leurs utilisations |
| EP3411066A1 (fr) | 2016-02-01 | 2018-12-12 | Eli Lilly and Company | Composés de fusion parathormone-anticorps anti-rankl |
| US10688181B2 (en) | 2016-06-27 | 2020-06-23 | The Regents Of The University Of California | Cancer treatment combinations |
| KR20190066607A (ko) * | 2016-09-23 | 2019-06-13 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
| AU2017331592A1 (en) | 2016-09-23 | 2019-04-11 | Teva Pharmaceuticals International Gmbh | Treating cluster headache |
| US20190071490A1 (en) | 2017-03-02 | 2019-03-07 | Beth Israel Deaconess Medical Center, Inc. | Preventing Post-Ictal Headaches |
| AR111845A1 (es) | 2017-05-03 | 2019-08-28 | Lilly Co Eli | Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos |
| MX2019015304A (es) * | 2017-06-21 | 2020-02-17 | Cephalon Inc | Amortiguador de lavado para cromatografia de intercambio cationico. |
| TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| TWI831762B (zh) | 2018-01-12 | 2024-02-11 | 美商安進公司 | Pac1抗體及其用途 |
| WO2019231800A1 (fr) | 2018-05-31 | 2019-12-05 | Eli Lilly And Company | Anticorps anti-cgrp pour le traitement des migraines liées aux menstruations |
| US20210340230A1 (en) | 2018-08-22 | 2021-11-04 | Eli Lilly And Company | Anti-CGRP Antibodies For Treatment-Resistant Patients |
| MX2021008267A (es) | 2019-01-08 | 2021-08-05 | H Lundbeck As | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp. |
| EP3744400A1 (fr) * | 2019-05-28 | 2020-12-02 | Etablissement Français du Sang | Ciblage de cellules car-t il-1rap et leur utilisation dans la leucémie myéloïde aiguë (aml) |
| WO2020239014A1 (fr) * | 2019-05-30 | 2020-12-03 | 山东博安生物技术有限公司 | Anticorps anti cgrp et son utilisation |
| CN114555792A (zh) | 2019-10-15 | 2022-05-27 | 伊莱利利公司 | 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系 |
| KR20230157986A (ko) | 2021-03-02 | 2023-11-17 | 체게에르페 다이어그노스틱스 게엠베하 | 편투통 발생의 치료 및/또는 저감 |
| WO2023161526A1 (fr) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | Conjugué constitué de ou comprenant au moins un ss-glucane ou un mannane |
| WO2024032750A1 (fr) * | 2022-08-11 | 2024-02-15 | 上海君实生物医药科技股份有限公司 | Anticorps anti-cgrp et utilisation |
| CN118271438A (zh) * | 2024-05-27 | 2024-07-02 | 上海宏成药业有限公司 | 抗cgrp抗体或其抗原结合片段及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU668349B2 (en) * | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
| DK0590058T3 (da) * | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| WO2006110214A2 (fr) * | 2005-04-08 | 2006-10-19 | Medimmune, Inc. | Anticorps diriges contre le metapneumovirus du mammifere |
| CN101309704B (zh) * | 2005-11-14 | 2012-10-10 | 礼纳特神经系统科学公司 | 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 |
| WO2007076336A1 (fr) | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Traitement de la migraine avec des anticorps anti-cgrp |
| CA2716424C (fr) * | 2008-03-04 | 2015-04-28 | Pfizer Limited | Procedes de traitement d'une douleur chronique |
| KR101304085B1 (ko) | 2008-03-04 | 2013-09-05 | 라브리스 바이올로직스 인코포레이티드 | 염증성 통증의 치료 방법 |
| AR081434A1 (es) * | 2010-06-10 | 2012-08-29 | Lilly Co Eli | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo |
-
2011
- 2011-05-31 AR ARP110101867A patent/AR081434A1/es active IP Right Grant
- 2011-05-31 JO JOP/2011/0177A patent/JO3330B1/ar active
- 2011-06-03 TW TW100119683A patent/TWI423818B/zh active
- 2011-06-07 MX MX2016005150A patent/MX363209B/es unknown
- 2011-06-07 AU AU2011265050A patent/AU2011265050B2/en active Active
- 2011-06-07 EA EA201270769A patent/EA022931B1/ru not_active IP Right Cessation
- 2011-06-07 NZ NZ603607A patent/NZ603607A/en unknown
- 2011-06-07 LT LTEP11792989.3T patent/LT2579894T/lt unknown
- 2011-06-07 NO NO11792989A patent/NO2579894T3/no unknown
- 2011-06-07 ME MEP-2017-280A patent/ME02862B/fr unknown
- 2011-06-07 CA CA2802102A patent/CA2802102C/fr active Active
- 2011-06-07 HU HUE11792989A patent/HUE038135T2/hu unknown
- 2011-06-07 US US13/154,538 patent/US9073991B2/en active Active
- 2011-06-07 SG SG2012084885A patent/SG185648A1/en unknown
- 2011-06-07 ES ES11792989.3T patent/ES2656000T3/es active Active
- 2011-06-07 EP EP11792989.3A patent/EP2579894B1/fr active Active
- 2011-06-07 MX MX2012014480A patent/MX340999B/es active IP Right Grant
- 2011-06-07 PL PL11792989T patent/PL2579894T3/pl unknown
- 2011-06-07 KR KR1020127032068A patent/KR101489566B1/ko active IP Right Grant
- 2011-06-07 CN CN201180028611.1A patent/CN102946905B/zh active Active
- 2011-06-07 SI SI201131359T patent/SI2579894T1/en unknown
- 2011-06-07 CN CN201410474677.9A patent/CN104292332B/zh active Active
- 2011-06-07 ES ES17201603T patent/ES2930321T3/es active Active
- 2011-06-07 WO PCT/US2011/039381 patent/WO2011156324A1/fr active Application Filing
- 2011-06-07 PT PT117929893T patent/PT2579894T/pt unknown
- 2011-06-07 EP EP17201603.2A patent/EP3318272B1/fr active Active
- 2011-06-07 RS RS20171265A patent/RS56638B1/sr unknown
- 2011-06-07 BR BR112012031501-3A patent/BR112012031501B1/pt active IP Right Grant
- 2011-06-07 DK DK11792989.3T patent/DK2579894T3/en active
- 2011-06-07 JP JP2013514281A patent/JP6021806B2/ja active Active
- 2011-07-06 UA UAA201212663A patent/UA109658C2/ru unknown
-
2012
- 2012-11-05 IL IL222885A patent/IL222885B/en active Protection Beyond IP Right Term
- 2012-11-28 ZA ZA2012/08996A patent/ZA201208996B/en unknown
-
2015
- 2015-04-20 HK HK15103793.6A patent/HK1203211A1/xx unknown
- 2015-06-04 US US14/730,270 patent/US9505838B2/en active Active
- 2015-11-02 IL IL242409A patent/IL242409B/en active IP Right Grant
-
2016
- 2016-06-28 JP JP2016127666A patent/JP6466883B2/ja active Active
- 2016-11-02 US US15/341,166 patent/US20170073403A1/en not_active Abandoned
-
2017
- 2017-12-21 HR HRP20171992TT patent/HRP20171992T1/hr unknown
-
2018
- 2018-01-18 CY CY20181100064T patent/CY1119789T1/el unknown
-
2019
- 2019-04-02 CY CY2019017C patent/CY2019017I2/el unknown
- 2019-04-02 HU HUS1900020C patent/HUS1900020I1/hu unknown
- 2019-04-05 NO NO2019017C patent/NO2019017I1/no unknown
- 2019-04-09 LU LU00112C patent/LUC00112I2/fr unknown
- 2019-04-11 NL NL300979C patent/NL300979I2/nl unknown
- 2019-04-12 LT LTPA2019011C patent/LTC2579894I2/lt unknown